NCT03114319: Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

NCT03114319
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Tumors harboring known activating KRAS, NRAS, HR+AS, BRAF or PTPN11 (SHP2) mutations
https://ClinicalTrials.gov/show/NCT03114319

Comments are closed.

Up ↑